About Index Trending news
Analyze
Pricing
Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
I work here Suggest edits
More info

Elsewhere

Contributors to this profile

Companies in the same industry

carmen valenzuela carmen valenzuela TapImmune TapImmune Semba Biosciences Semba Biosciences CareDx CareDx Viroblock Viroblock Valentia Biopharma Valentia Biopharma SeqLL, LLC SeqLL, LLC Versago Vascular Access Versago Vascular Access Prostagene Prostagene Prestodiag Prestodiag

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 4
Add info
Add round
20 Jul 2017
$50,500,000
Venture capital (Series C)
NEA, Omega Funds, TPG Biotechnology Partners, +2

NEA leads $50.5 mln Series C round in Trevi Therapeutics

PE Hub
08 Jan 2015
$15,000,000
Debt financing
Square 1 Bank, Solar capital

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor

abladvisor
06 Nov 2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec 2012
$6,564,102
Venture capital